Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eberhard Ritz

Showing results (321-330 of 334) with videos related to

Pageof 34
Sort By:
Experimental Gerontology|January 22, 2013
Circulating aldosterone and mortality in female nursing home residentsAndreas Tomaschitz, Stefan Pilz, Burkert Pieske, et al.
Journal of the American Society of Nephrology : JASN|July 25, 2000
Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized ratsKerstin Amann, Lars Christian Rump, Aurelia Simonaviciene, et al.
Blood Pressure|June 9, 2004
HYDRA: possible determinants of unsatisfactory hypertension control in German primary care patientsU Muscha Steckelings, Martina Stoppelhaar, Arya M Sharma, et al.
Journal of the American Society of Nephrology : JASN|July 28, 2007
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) StudyDanilo Fliser, Barbara Kollerits, Ulrich Neyer, et al.
Clinical and Experimental Hypertension (New York, N.Y. : 1993)|May 3, 2014
Marinobufagenin in essential hypertension and primary aldosteronism: a cardiotonic steroid with clinical and diagnostic implicationsAndreas Tomaschitz, Grzegorz Piecha, Eberhard Ritz, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 9, 2014
Homoarginine, kidney function and cardiovascular mortality riskAndreas Tomaschitz, Andreas Meinitzer, Stefan Pilz, et al.
Kidney International|July 14, 2011
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)Charles A Herzog, Richard W Asinger, Alan K Berger, et al.
The American Journal of the Medical Sciences|February 4, 2015
Homoarginine in patients with primary hyperparathyroidismAndreas Tomaschitz, Nicolas Verheyen, Martin Gaksch, et al.
Lancet (London, England)|November 5, 2015
The double challenge of resistant hypertension and chronic kidney diseasePatrick Rossignol, Ziad A Massy, Michel Azizi, et al.
Journal of the American Society of Nephrology : JASN|January 9, 2015
Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D StudiesChristiane Drechsler, Graciela Delgado, Christoph Wanner, et al.
Pageof 34

Showing results (321-330 of 334) with videos related to

Sort By:
Pageof 34
Experimental Gerontology|January 22, 2013
Circulating aldosterone and mortality in female nursing home residentsAndreas Tomaschitz, Stefan Pilz, Burkert Pieske, et al.
Journal of the American Society of Nephrology : JASN|July 25, 2000
Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized ratsKerstin Amann, Lars Christian Rump, Aurelia Simonaviciene, et al.
Blood Pressure|June 9, 2004
HYDRA: possible determinants of unsatisfactory hypertension control in German primary care patientsU Muscha Steckelings, Martina Stoppelhaar, Arya M Sharma, et al.
Journal of the American Society of Nephrology : JASN|July 28, 2007
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) StudyDanilo Fliser, Barbara Kollerits, Ulrich Neyer, et al.
Clinical and Experimental Hypertension (New York, N.Y. : 1993)|May 3, 2014
Marinobufagenin in essential hypertension and primary aldosteronism: a cardiotonic steroid with clinical and diagnostic implicationsAndreas Tomaschitz, Grzegorz Piecha, Eberhard Ritz, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 9, 2014
Homoarginine, kidney function and cardiovascular mortality riskAndreas Tomaschitz, Andreas Meinitzer, Stefan Pilz, et al.
Kidney International|July 14, 2011
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)Charles A Herzog, Richard W Asinger, Alan K Berger, et al.
The American Journal of the Medical Sciences|February 4, 2015
Homoarginine in patients with primary hyperparathyroidismAndreas Tomaschitz, Nicolas Verheyen, Martin Gaksch, et al.
Lancet (London, England)|November 5, 2015
The double challenge of resistant hypertension and chronic kidney diseasePatrick Rossignol, Ziad A Massy, Michel Azizi, et al.
Journal of the American Society of Nephrology : JASN|January 9, 2015
Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D StudiesChristiane Drechsler, Graciela Delgado, Christoph Wanner, et al.
Pageof 34